ProCE Banner Activity

How We Will Apply New Results in Endometrial, Ovarian, and Cervical Cancers From IGCS 2021

Conference Coverage
Clinical Thought

Gynecologic oncology experts share their takeaways from new clinical data presented at the 2021 IGCS annual meeting for the treatment of endometrial, ovarian, and cervical cancers.

This ClinicalThought is intended for healthcare professionals practicing medicine outside of the United States.

Released: September 30, 2021

Expiration: September 29, 2022

Share

Faculty

Alexandra Leary

Alexandra Leary, MD, PhD

Co-Director, Department of Medical Oncology
Medical Oncologist, Gynecology
Team Leader, Gynecologic Translational Research Lab, ISERM U981
Institut Gustave Roussy
Past-President, GINEGEPS, GINECO Group on Early Phase Trials
Villejuif, France

Domenica Lorusso

Domenica Lorusso, MD, PhD

Associate Professor 
Catholic University of Sacred Heart
Haear of Clinical Research Development Unit
Fondazione Policlinico Gemelli IRCCS
Rome, Italy

Supporters

This educational activity is supported by an educational grant from

GlaxoSmithKline

Faculty Disclosure

Primary Author

Alexandra Leary, MD, PhD

Co-Director, Department of Medical Oncology
Medical Oncologist, Gynecology
Team Leader, Gynecologic Translational Research Lab, ISERM U981
Institut Gustave Roussy
Past-President, GINEGEPS, GINECO Group on Early Phase Trials
Villejuif, France

Alexandra Leary, MD, PhD, has disclosed that she has received funds for research support from Ability, AstraZeneca, Clovis, GlaxoSmithKline, MSD, and Tesaro; consulting fees from Ability, AstraZeneca, Biocad, Clovis, Merck Serono (paid to her institution), MSD, Seattle Genetics, Tesaro, and Zentalis; and other financial or material support from AstraZeneca, Clovis, GlaxoSmithKline, and Tesaro.

Domenica Lorusso, MD, PhD

Associate Professor 
Catholic University of Sacred Heart
Haear of Clinical Research Development Unit
Fondazione Policlinico Gemelli IRCCS
Rome, Italy

Domenica Lorusso, MD, PhD, has disclosed that she has received consulting fees from Amgen, AstraZeneca, Clovis, GlaxoSmithKline, MSD, and Pharmamar; fees for non-CME/CE services from MSD; and other financial or material support from AstraZeneca, Clovis, GlaxoSmithKline, and Pharmamar.